Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check8 days agoChange DetectedRevision updated to v3.3.4, replacing the previous v3.3.3.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedFooter shows Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check57 days agoChange DetectedA new revision label 'v3.3.2' appears, replacing 'v3.2.0', indicating a site version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedRemoved the generic government funding and operating status notice from the page; study details and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check79 days agoChange DetectedNo changes detected; the two screenshots show the same study details page.SummaryDifference0.4%

- Check108 days agoChange Detected- Added a government funding notice with operational details and links; - Updated version to v3.2.0; - Removed reference to v3.1.0.SummaryDifference3%

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.